

From the Department of Academic Biochemistry, Royal Marsden Hospital, London, United Kingdom; Frontier Science (Scotland) Ltd, Kinraig, Kingussie, Scotland; National Cancer Institute, National Institutes of Health, Bethesda, MD; Departments of Medical Oncology and Medicine, Institut Jules Bordet, Université Libre de Bruxelles; Breast European Adjuvant Studies Team, Brussels, Belgium; Department of Public Health, School of Nursing, University of Athens, Athens, Greece; TARGOS Molecular Pathology GmbH, Kassel, Germany; Roche Professional Diagnostics, F. Hoffmann-La Roche Ltd, Basel, Switzerland; VM Institute of Research, Montreal, Quebec, Canada; Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Milan, Italy; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; and Emory Winship Cancer Institute, Atlanta, GA.

Submitted August 21, 2008; accepted January 12, 2009; published online ahead of print at www.jco.org on April 13, 2009.

Supported in part by NHS (National Health Service) funding to the Royal Marsden National Institute for Health Research Biomedical Research Centre (M.D.).

Presented in part at the 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, TX.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

Corresponding author: Mitch Dowsett, PhD, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, United Kingdom; e-mail: mitch.dowsett@icr.ac.uk.

The Acknowledgment is included in the full-text version of this article, available online at www.jco.org. It is not included in the PDF version (via Adobe® Reader®).

© 2009 by American Society of Clinical Oncology

0732-183X/09/2718-2962/\$20.00

DOI: 10.1200/JCO.2008.19.7939

Disease-Free Survival According to Degree of *HER2* Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett, Marion Procter, Worta McCaskill-Stevens, Evandro de Azambuja, Urania Dafni, Josef Rueschoff, Bruce Jordan, Stella Dolci, Mark Abramovitz, Oliver Stoss, Giuseppe Viale, Richard D. Gelber, Martine Piccart-Gebhart, and Brian Leyland-Jones

ABSTRACT

Purpose

To determine whether (1) immunohistochemical (IHC) *HER2* status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) *HER2*/CEP17 ratio or (2b) *HER2* gene copy number, or (3) polysomy significantly influenced clinical outcome for patients with human epidermal growth factor receptor 2 (*HER2*) –positive breast cancer enrolled in the Herceptin Adjuvant trial of trastuzumab versus no trastuzumab administered after completion of chemotherapy.

Patients and Methods

IHC and/or FISH analyses were performed locally and required central confirmation as indicating *HER2* positivity for trial entry. FISH data from the central *HER2* analysis on patients in the 1-year trastuzumab and no trastuzumab arms were assessed in relation to disease-free survival (DFS) after a median 2 years of follow-up.

Results

Central FISH results were available for 2,071 (61%) of the 3,401 patients randomized to the 2 arms. Among patients with FISH-positive disease, (1) the hazard ratios for trastuzumab versus no trastuzumab were 0.56 (95% CI, 0.32 to 0.99) for locally IHC2+ cases ($n = 340$) and 0.80 (95% CI, 0.40 to 1.61) for centrally IHC2+ cases ($n = 299$). There was no significant prognostic relationship between (2a) *HER2* FISH ratio, (2b) *HER2* copy number, or (3) polysomy and DFS in the control arm or predictive relationship defining differential benefit from trastuzumab.

Conclusion

There was no evidence for reduced benefit of trastuzumab in *HER2* IHC2+ FISH+ cases. The degree of *HER2* amplification does not influence prognosis or benefit from adjuvant trastuzumab in patients treated with prior adjuvant chemotherapy.

J Clin Oncol 27:2962-2969. © 2009 by American Society of Clinical Oncology

INTRODUCTION

The human epidermal growth factor receptor 2 (*HER2*) is a 185-kd glycoprotein with tyrosine kinase activity. Its overexpression in breast cancer is a key feature of the pathobiology of the disease and is associated with poorer prognosis.^{1,2} Amplification is the primary mechanism of *HER2* overexpression.³ Approximately 15% of all newly diagnosed invasive breast carcinomas are *HER2* positive (*HER2*+) but the proportion is higher among tumors with higher grade and patients with positive nodal status. As a result approximately 25% of patients considered appropriate for adjuvant chemotherapy are *HER2* positive.⁴

Trastuzumab is a humanized monoclonal antibody directed to the external domain of *HER2*. Four large and one small randomized trial of trastuzumab (Herceptin; Genentech, South San Francisco, CA) in early breast cancer have shown that this treatment can significantly improve the patient outcome when trastuzumab is applied alongside and/or subsequent to adjuvant chemotherapy.⁵⁻⁸ Decreases in recurrence and mortality of approximately one half and one third, respectively, have been demonstrated. As a result trastuzumab has become standard of care for the treatment of *HER2*+ early breast cancer.

The diagnosis of *HER2* overexpression is based on two analytic approaches that are most commonly

used in conjunction: **immunohistochemistry** (IHC) and in situ hybridization (ISH).⁹ IHC reveals overexpression of HER2 on the cell membrane. The degree of staining is most frequently described on a scale of 0 to 3, with 3+ being considered unequivocally positive (> 10% of cells with intense circumferential membrane staining according to US Food and Drug Administration, or > 30% immunostained tumor cells as per the recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommendations⁹), 2+ equivocal and 0/1+ negative. ISH reveals the number of *HER2* gene copies per cell and has been most commonly conducted with a **fluorescence in situ hybridization (FISH)** probe. A second probe that hybridizes to the centromeric region of chromosome 17 (CEP17) can be used and this allows the ratio of *HER2* gene copies per chromosome to be calculated. A ratio of 2.0 or greater is regarded as positive according to the US Food and Drug Administration recommendations, though a cutoff of 2.2 or greater has been proposed more recently in the ASCO/CAP guidelines.⁹

The aims of the current study were to determine whether within the control and 1-year treatment arms of HERceptin Adjuvant (HERA), the largest of the adjuvant trials, there were significant differences in clinical outcome according to IHC status (ie, 2+ or 3+) in FISH-amplified cases or according to the degree of FISH amplification. We also assessed the impact of increased *HER2* gene copy number as a result of **polysomy** on prognosis and treatment benefit and the impact of polysomy itself in an HER2-positive population.

PATIENTS AND METHODS

The HERA (Breast International Group [BIG] 01-01) trial is an international, intergroup, open-label, phase III randomized trial involving women with HER2-positive (overexpressed or amplified) early stage invasive breast cancer who completed locoregional therapy (surgery plus radiotherapy where indicated) and a minimum of 4 courses of chemotherapy. The study design, eligibility criteria, treatment schedules, monitoring and statistical analysis plan have been described in detail elsewhere.⁵ Eligibility criteria included node-positive disease or node-negative disease if the pathological tumor size was greater than 1 cm. The institutional review board at each of the participating institutions approved the study protocol. All patients gave written informed consent.

After local regional therapy patients were randomly assigned to one of three groups: observation only (no trastuzumab), 8 mg/kg trastuzumab intravenously as a loading dose followed by 6 mg/kg every 3 weeks for 1 year, or the same schedule of trastuzumab for 2 years: outcome data is not yet available for the 2-year arm. Randomisation took place within 7 weeks from the last chemotherapy cycle or 6 weeks from the end of radiotherapy or definitive surgery, whichever was last.

The primary end point of the trial was disease-free survival (DFS), and this is the only end point reported here. The data presented here are from the analysis conducted after a median 2-years of follow-up.¹⁰ DFS was defined as time from randomisation to the first occurrence of any of the following events: recurrence of breast cancer at any site; the development of ipsilateral or contralateral breast cancer including ductal carcinoma in situ; second nonbreast malignant disease other than basal cell or squamous cell carcinoma in situ of the cervix; or death from any cause without documentation of a cancer-related event.

Central confirmation (TARGOS, Kassel, Germany) of the HER2-positive status of tumors was required in all cases before randomisation as follows. A result on IHC (DAKO, HercepTest) at the central lab of 3+ (> 10% stained cells) was required for confirmation of the status of tumors assessed by the participating institution as 3+, and a positive result from FISH (PathVysion, Vysis; *HER2*:CEP17 ratio \geq 2.0) for *HER2* amplifica-

tion was required for tumors that were assessed in the participating institution as IHC2+ or FISH-positive. FISH was not performed before randomisation on cases that were locally deemed IHC3+ and confirmed IHC3+ centrally. The results from both local and central analyses were recorded in the case report forms.

For the purposes of this study additional FISH analyses were performed retrospectively for patients not having a central FISH analysis before randomisation. Tissue sections of 4 microns were used from one of two resources: (1) sections cut at the time of central analysis and stored at TARGOS; (2) sections taken in TransHERA, a parallel project to HERA in which formalin fixed paraffin embedded (FFPE) tumor excision blocks have been collected retrospectively for translational research studies. These retrospective FISH analyses were conducted either at TARGOS or in the European Institute of Oncology (Milan, Italy) after an initial pilot study to ensure common standardized procedures.

Statistics

The database closure for this analysis was February 14, 2006. Between December 2001 and June 2005, there were 1,698 patients randomized to observation (no trastuzumab) only and 1,703 patients randomly assigned to 1-year trastuzumab. We calculated Kaplan-Meier estimates for 3 year DFS rates according to subgroups and estimated SEs and 95% CIs according to the Greenwood formula.^{11,12} We calculated Kaplan-Meier estimates for DFS curves for observation patients according to defined subgroups. Tests for interaction between treatment, respective pathological parameter and DFS were carried out using Cox proportional hazard models.

RESULTS

Central FISH results were available on 2,071 (61%) of the 3,401 patients randomized to the 1-year trastuzumab or no trastuzumab arms of HERA. Of these 1,131 results were derived during the eligibility screening and 940 were derived from material banked either as spare sections at TARGOS or as sections taken for TransHERA. DFS was similar for the subgroup of 2,071 patients at 3 years to that for the overall set of 3,401 patients both for the treated (80.6% and 81.2%, respectively) and untreated arms (74.3% and 75.1%, respectively). The HR for trastuzumab versus no trastuzumab in the subgroup was 0.69 (95% CI, 0.55 to 0.86) versus 0.64 (95% CI, 0.54 to 0.76) in the overall population.

Effectiveness of Trastuzumab in IHC2+ FISH+

To determine whether patients with IHC2+ FISH+ breast cancer derived significant benefit from trastuzumab, analyses were performed in two partially overlapping populations: (i) in the 340 cases that were locally IHC2+ and centrally FISH+ the hazard ratio was 0.56 (95% CI, 0.32 to 0.99); and (ii) in the 299 cases that were centrally IHC2+ and centrally FISH+ the hazard ratio was 0.80 (95% CI, 0.40 to 1.61). The overlap between these populations was only 53 patients, mainly because the majority of local IHC2+ central FISH+ cases did not have a central IHC result and the majority of the central IHC2+ central FISH+ cases were local IHC3+.

We examined the ER status for patients in the 2 IHC2+ FISH+ subgroups described above because it is known that ER positivity and HER-2 protein levels are inversely correlated.¹³ In the locally IHC2+ FISH+ subgroup, 60.3% of cases were ER+ compared with 45.6% in the locally IHC3+ FISH+ ($P < .0001$). Similarly, 63.2% of the centrally IHC2+ FISH+ cases were ER+ compared with 42.2% of the centrally IHC3+ FISH+ ($P < .0001$).

Relationship Between FISH Ratio and HER2 Copy Number With Prognosis and Benefit From Trastuzumab

The distribution and range of FISH ratios and *HER2* copy numbers are shown in Figures 1A and 1B, respectively. Analyses of FISH ratio and *HER2* copy number with clinical outcome were conducted by comparison of approximate quartiles of the respective data sets: exact quartiles were calculated and then the closest integer cutoff was applied to define the 4 approximate quartiles (shown in Fig 1A and 1B). There was no significant relationship between FISH ratio levels or *HER2* copy number on prognosis in the untreated arm (Fig 2A and 2B). Although there was an apparent trend towards decreasing effectiveness of trastuzumab with increasing FISH ratio (Fig 3A; Table 1) this was not statistically significant ($P = .29$) and the trend was less evident when *HER2* was quantified by copy number only ($P = .38$) (Fig 3B; Table 2). FISH ratio was found to correlate inversely with ER-positivity (based on locally performed ER analyses): the proportion ER+ was 64%, 46%, 46% and 39% for the categories of more




Fig 1. Distribution of (A) *HER2* FISH ratio, (B) *HER2* copy number, (C) CEP17 copy number (for patients with FISH ratio ≥ 2) for patients in the 1-year trastuzumab and observation arms of the HERA trial showing cut-offs used for comparative analysis. CEP17, chromosome 17 centromere; FISH, fluorescence in situ hybridization; *HER2*, human epidermal growth factor receptor 2 gene.




Fig 2. Disease-free survival according to (A) *HER2* FISH ratio, (B) *HER2* copy number, and (C) CEP17 copy number (for patients with FISH ratio ≥ 2) in the observation arm of the HERA trial: details of the populations defined by cut-offs shown in Figure 1 and (D) CEP17 copy number according to NCCTG cut-offs (see text). CEP17, chromosome 17 centromere; FISH, fluorescence in situ hybridization; *HER2*, human epidermal growth factor receptor 2 gene.

than 2.0 to 4.0, more than 4.0 to 6.0, more than 6.0 to 8.0 and more than 8.0, respectively ($P < .0001$).

HER2 FISH Ratios Less Than 2.0

There were only 41 patients with tumors that by central FISH analysis had *HER2* ratios less than 2.0. We therefore performed no evaluation of possible benefit from trastuzumab in this subgroup.

Relationship Between Chromosome 17 (chr17) Polysomy With Prognosis and Benefit From Trastuzumab

The distribution of chr17 copy numbers/cell is shown in Figure 1C. Two sets of comparative analyses were conducted:




Fig 3. Forest plots of the relative benefit from trastuzumab according to (A) HER2 FISH ratio, (B) HER2 copy number, and (C) CEP17 copy number (for patients with FISH ratio ≥ 2) in the HERA trial: details of the populations defined by cut-offs shown in Figure 1 and (D) CEP17 copy number according to NCCTG cut-offs (see text). CEP17, chromosome 17 centromere; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2 gene; HR, hazard ratio; IHC, immunohistochemistry; obs, observation; T, trastuzumab.

(i) between three groups defined by copy numbers/cell ≤ 2.0, 2.0 to 3.0 and more than/≥ 3.0; and (ii) between groups defined as polysomic or not where polysomy was considered as at least 30% of nuclei with 3 or more CEP17 signals. For both (i) and (ii) there was no significant difference in prognosis (Fig 2C and 2D) and no significant difference in the effectiveness of trastuzumab (Fig 3C and 3D; Tables 3 and 4) according to chr17 copy number.

DISCUSSION

Large randomized trials have established trastuzumab as the standard of care in patients with early HER2-positive breast cancer also suitable for treatment with chemotherapy.⁵⁻⁷ Although there has been much debate about the appropriate method of diagnosing HER-2 status widely accepted guidelines have recently been published that confirm

Table 1. DFS by Central FISH Ratio

Population/Treatment	No. of Patients	DFS Events		3-Year DFS		Hazard Ratio	95% CI
		No.	%	%	95% CI		
2 ≤ FISH ratio ≤ 4							
1 year of trastuzumab	229	22	9.6	85.0	75.5 to 91.1	0.56	0.33 to 0.94
Observation	224	38	17.0	72.4	60.4 to 81.3		
4 < FISH ratio ≤ 6							
1 year of trastuzumab	307	35	11.4	82.8	75.9 to 87.9	0.57	0.37 to 0.87
Observation	286	53	18.5	73.1	65.1 to 79.6		
6 < FISH ratio ≤ 8							
1 year of trastuzumab	251	32	12.7	82.8	75.6 to 88.0	0.74	0.47 to 1.18
Observation	239	41	17.2	77.6	69.9 to 83.6		
FISH ratio > 8							
1 year of trastuzumab	244	43	17.6	75.1	67.1 to 81.4	0.91	0.60 to 1.37
Observation	250	48	19.2	76.2	69.0 to 82.0		
Other: unknown or < 2							
1 year of trastuzumab	672	86	12.8	79.2	73.3 to 83.9	0.59	0.45 to 0.77
Observation	699	141	20.2	73.7	69.3 to 77.5		

Abbreviations: DFS, disease-free survival; FISH, fluorescence in situ hybridization.

the combined use of IHC and/or FISH as an appropriate means of establishing positivity.⁹ It is clear however that the degree of HER-2 overexpression/amplification varies markedly in patients considered positive: the wide range and the continuum of this variability is well demonstrated by the analyses shown in this study (Fig 1).

The relatively low level of HER-2 protein expression in the subgroup of patients with IHC2+/FISH+ disease might conceivably lead to a lower degree of benefit in such patients. The design of the central testing algorithm in HERA resulted in there being two sets of samples available to address this issue. In both the locally IHC2+/FISH+ and centrally IHC2+/FISH+ cohorts, ER was positive in a greater proportion than in the corresponding IHC3+ cohort. Given that there is a well-described inverse relationship between HER-2 protein levels and ER positivity in breast cancers,¹³

these data provide supporting evidence for lower levels of HER-2 protein in both of the IHC2+/FISH+ groups compared with IHC3+ cases. We found a statistically significant benefit in the 340 patients (with 49 events) that were diagnosed locally with IHC 2+ and centrally with FISH+ disease. For the group of 299 patients that was diagnosed centrally with IHC2+ and FISH+ disease, there was no significant benefit found but the 95% CI for the hazard ratio included the overall hazard ratio (0.64) and there was no statistically significant difference from the overall result by the test of heterogeneity. Data from the NSABP B31 trial also suggested benefit in the IHC2+/FISH+ group while the NCCTG N9831 trial did not. In both cases, however, the number of DFS events was very low^{14,15} and a meta-analysis is needed to provide useful information.

Table 2. DFS According to Central *HER2* Gene Copy Number

Population/Treatment	No. of Patients	DFS Events		3-Year DFS		Hazard Ratio	95% CI
		No.	%	%	95% CI		
4 ≤ <i>HER2</i> copy number ≤ 9							
1 year of trastuzumab	239	26	10.9	82.3	72.5 to 88.9	0.55	0.34 to 0.90
Observation	229	42	18.3	73.0	62.5 to 81.1		
9 < <i>HER2</i> copy number ≤ 13							
1 year of trastuzumab	241	30	12.4	83.8	77.1 to 88.6	0.73	0.45 to 1.16
Observation	239	40	16.7	73.8	64.2 to 81.1		
13 < <i>HER2</i> copy number ≤ 18							
1 year of trastuzumab	281	27	9.6	85.6	78.7 to 90.4	0.51	0.32 to 0.82
Observation	275	50	18.2	77.2	70.1 to 82.9		
<i>HER2</i> copy number > 18							
1 year of trastuzumab	262	47	17.9	72.6	63.7 to 79.7	0.90	0.60 to 1.34
Observation	257	50	19.5	74.6	67.3 to 80.6		
Other: unknown or < 4							
1 year of trastuzumab	680	88	12.9	79.2	73.4 to 83.8	0.60	0.46 to 0.79
Observation	698	139	19.9	74.0	69.6 to 77.8		

Abbreviation: DFS, disease-free survival.

Table 3. DFS by Central Chromosome 17 Copy Number in Tumors With FISH Ratio ≥ 2

Population/Treatment	No. of Patients	No. of DFS Events		3-Year DFS		Hazard Ratio	95% CI
		No.	%	%	95% CI		
CEP17 ≤ 2 and FISH ratio ≥ 2							
1 year of trastuzumab	430	55	12.8	81.8	76.1 to 86.3	0.64	0.45 to 0.90
Observation	416	79	19.0	75.0	68.8 to 80.1		
2 < CEP17 < 3 and FISH ratio ≥ 2							
1 year of trastuzumab	451	64	14.2	80.1	74.7 to 84.5	0.87	0.62 to 1.22
Observation	461	73	15.8	78.7	73.2 to 83.2		
CEP17 ≥ 3 and FISH ratio ≥ 2							
1 year of trastuzumab	150	13	8.7	84.4	71.6 to 91.8	0.39	0.20 to 0.75
Observation	122	28	23.0	63.9	49.3 to 75.3		
Other: CEP17 count unknown and/or FISH ratio < 2							
1 year of trastuzumab	672	86	12.8	79.2	73.3 to 83.9	0.59	0.45 to 0.77
Observation	699	141	20.2	73.7	69.3 to 77.5		

Abbreviations: DFS, disease-free survival; CEP17, centromeric region of chromosome 17; FISH, fluorescence in situ hybridization.

The HERA trialists have recently shown that the proportional benefit from trastuzumab does not vary substantially across subgroups of HER2-positive patients that differ markedly in prognosis.¹⁶ By the current analyses we have now established that there are no marked differences in benefit according to the degree of amplification whether this is expressed in terms of the *HER2/CEP17* ratio or the absolute number of *HER2* copies; the latter varies from the former because of the presence of polyploidy of chr17 that can be assessed from the use of the 2-probe FISH test used in this study. It is also notable that prognosis did not differ in the nontrastuzumab arm according to the level of amplification. All patients on HERA received adjuvant chemotherapy⁵; therefore this result reflects prognosis after chemotherapy and the clinical outcome would in part reflect benefit from that chemotherapy. The amplicon which harbors *HER2* contains several other biologically significant genes that may or may not be coamplified with *HER2*¹⁷ and influence the benefit from certain chemotherapy, such as the apparent interaction between *TOP2A* and benefit from anthracyclins.^{18,19} Such interactions may have influenced our ability to identify any relationship of *HER2* amplification and prognosis per se.

Our data indicate that differences in HER2 expression resulting from different FISH ratios, *HER2* copy number or ploidy have no significant relationship with benefit from trastuzumab. This implies that there is a strong threshold effect whereby any degree of amplification above the cutoff ratio of 2.0 is of equal clinical significance. A consequence is that misdiagnosis of patients as having HER2-negative tumors, which inevitably is most likely to occur at amplification levels close to the threshold,²⁰ would deny a patient the potential of deriving full benefit of trastuzumab. This is in marked contrast to the strong direct relationship between expression levels for the other major target of breast cancer therapy, ER- α , and benefit from tamoxifen.²¹ This latter relationship indicates that while misdiagnosis of low-positive ER patients is highly undesirable the loss of potential benefit from tamoxifen will be small for most patients.

The precise level of the threshold of HER-2 amplification/over-expression in relation to benefit from trastuzumab has recently been brought into doubt by data from the NSABP-B31 trial that indicate that the subgroup of 174 patients conventionally considered as having HER2-negative disease (centrally tested IHC and FISH negative) appeared to benefit from trastuzumab (relative risk for DFS, 0.34; 95%

Table 4. DFS by Polysomy Status According to NCCTG Criteria

Population/Treatment	No. of Patients	DFS Events		3-Year DFS		Hazard Ratio	95% CI
		No.	%	%	95% CI		
Polysomy and FISH ratio ≥ 2							
1 year of trastuzumab	440	52	11.8	81.5	75.6 to 86.2	0.67	0.47 to 0.96
Observation	443	77	17.4	74.3	67.9 to 79.6		
No polysomy and FISH ratio ≥ 2							
1 year of trastuzumab	591	80	13.5	81.2	76.3 to 85.2	0.70	0.52 to 0.94
Observation	556	103	18.5	76.6	71.9 to 80.6		
Other: polysomy status unknown and/or FISH ratio < 2							
1 year of trastuzumab	672	86	12.8	79.2	73.3 to 83.9	0.59	0.45 to 0.77
Observation	699	141	20.2	73.7	69.3 to 77.5		

Abbreviations: DFS, disease-free survival; NCCTG, North Central Cancer Treatment Group; FISH, fluorescence in situ hybridization.

CI, 0.14 to 0.80).²² A similar analysis in 103 patients in the NCCTG trial also showed a trend towards benefit of trastuzumab but this was not statistically significant (HR 0.51; 95% CI, 0.21 to 1.2).¹⁵ Similarly the HERA trial had only 41 patients that could contribute to this analysis and we deemed it inappropriate to analyze this small group but hope to contribute these to a more detailed assessment together with samples from the other trials to clarify this issue.

Chromosome 17 polysomy (defined as at least one more copy of chromosome 17 than normal) in the absence of *HER2* amplification is sometimes associated with 2+ IHC staining but rarely with 3+ indicating that such polysomy has little influence on *HER2* gene expression in breast carcinoma²³ and no apparent influence on the clinical presentation or behavior in *HER2*-negative tumors.²⁴ In the present study we assessed the importance of polysomy in the *HER2*-positive population. There is no agreed definition of cut-offs for polysomy. We applied an analysis which used a cutoff of a mean 3 CEP17 signals per cell as mentioned in the recent ASCO/CAP guidelines⁹ and also a cutoff of at least 3 copies per cell in at least 30% of nuclei as used for analysis of the NCCTG trial.²⁵ The latter gave a substantially larger population that was considered polysomic but in neither case was there a statistically significant association with clinical outcome. There were insufficient patients to assess the possible importance of polysomy according to different levels of gene amplification.

The strengths of the current work include the analysis being conducted within a randomized trial and the FISH analysis being conducted centrally in just two well-controlled laboratories that had conducted a pilot study to ensure comparability between them. The study population amounted to only 61% of the HERA population in the 1-year and no trastuzumab groups and as such there must be a caveat that results may have been different in the whole population. However, this seems unlikely since the clinical outcome for the subpopulation was very similar to that in the overall trial. The subset of samples amounted to over 1,000 cases in each arm giving a high probability of finding any substantial effect on prognosis. These same numbers are, however, modest to determine whether there is a significant interaction with treatment, such that only a major interaction is incompatible with the overall data from the HERA trial; collaborative overview analysis with other trialists is envisaged to provide greater statistical power for analyses of interaction with treatment.

In conclusion, the current analysis indicates that in *HER2*-positive early breast cancer there is no significant effect of *HER2* FISH

ratio, *HER2* copy number or polysomy of chr17 on either prognosis or benefit from trastuzumab in a chemotherapy-treated population.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Bruce Jordan, Roche Professional Diagnostics (C) **Consultant or Advisory Role:** Mitch Dowsett, Roche (C), DAKO (C), GlaxoSmithKline (C); Josef Rueschoff, Roche (C); Martine Piccart-Gebhart, Roche (C), GlaxoSmithKline (C); Brian Leyland-Jones, Roche (C) **Stock Ownership:** None **Honoraria:** Mitch Dowsett, Roche; Martine Piccart-Gebhart, Roche, GlaxoSmithKline; Brian Leyland-Jones, Roche **Research Funding:** Mitch Dowsett, Roche, GlaxoSmithKline; Josef Rueschoff, Roche; Oliver Stoss, Roche; Giuseppe Viale, Roche; Richard D. Gelber, Roche; Brian Leyland-Jones, Roche **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Mitch Dowsett, Wortá McCaskill-Stevens, Josef Rueschoff, Giuseppe Viale, Richard D. Gelber, Martine Piccart-Gebhart, Brian Leyland-Jones

Financial support: Bruce Jordan

Administrative support: Mark Abramovitz

Provision of study materials or patients: Josef Rueschoff, Oliver Stoss, Giuseppe Viale

Collection and assembly of data: Mitch Dowsett, Martine Piccart-Gebhart, Evandro de Azambuja, Urania Dafni, Josef Rueschoff, Stella Dolci, Oliver Stoss, Giuseppe Viale, Richard D. Gelber

Data analysis and interpretation: Mitch Dowsett, Martine Piccart-Gebhart, Wortá McCaskill-Stevens, Evandro de Azambuja, Urania Dafni, Josef Rueschoff, Bruce Jordan, Stella Dolci, Oliver Stoss, Giuseppe Viale, Richard D. Gelber, Martine Piccart-Gebhart, Brian Leyland-Jones

Manuscript writing: Mitch Dowsett, Richard D. Gelber

Final approval of manuscript: Mitch Dowsett, Martine Piccart-Gebhart, Wortá McCaskill-Stevens, Evandro de Azambuja, Urania Dafni, Josef Rueschoff, Bruce Jordan, Stella Dolci, Mark Abramovitz, Oliver Stoss, Giuseppe Viale, Richard D. Gelber, Martine Piccart-Gebhart, Brian Leyland-Jones

REFERENCES

- Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the *HER-2/neu* oncogene. *Science* 235:177-182, 1987
- Slamon DJ, Godolphin W, Jones LA, et al: Studies of the *HER-2/neu* proto-oncogene in human breast and ovarian cancer. *Science* 244:707-712, 1989
- Akiyama T, Sudo C, Ogawara H, et al: The product of the human *c-erbB-2* gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. *Science* 232:1644-1646, 1986
- Bartlett JM, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those

with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. *J Clin Oncol* 25:4423-4430, 2007

- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in *HER2*-positive breast cancer. *N Engl J Med* 353:1659-1672, 2005

- Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable *HER2*-positive breast cancer. *N Engl J Med* 353:1673-1684, 2005

- Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC γ T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC γ TH) with docetaxel, carboplatin

and trastuzumab (TCH) in *Her2neu* positive early breast cancer patients. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006

- Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *N Engl J Med* 354:809-820, 2006

- Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 25:118-145, 2007

- Smith I, Procter M, Gelber RD, et al: HERA study team: 2-year follow-up of trastuzumab after adjuvant chemotherapy in *HER2*-positive breast cancer: A randomised controlled trial. *Lancet* 369:29-36, 2007

11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457-481, 1958
12. Greenwood M: A report on the natural duration of cancer, in: *Reports on Public Health and Medical Subjects* (vol 33). London, United Kingdom, HM Stationery Office, 1926, pp 1-26
13. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst* 95:142-153, 2003
14. Paik S, Kim C, Jeong J, et al: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. *J Clin Oncol* 25:5s, 2007 (suppl; abstr 511)
15. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. *J Clin Oncol* 25:6s, 2007 (suppl; abstr 512)
16. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Ann Oncol* 19:1090-1096, 2008
17. Arriola E, Marchio C, Tan DS, et al: Genomic analysis of the *HER2/TOP2A* amplicon in breast cancer and breast cancer cell lines. *Lab Invest* 88:491-503, 2008
18. Di Leo A, Gancberg D, Larsimont D, et al: *HER-2* amplification and topoisomerase II α gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. *Clin Cancer Res* 8:1107-1116, 2002
19. Tanner M, Isola J, Wiklund T, et al: Scandinavian Breast Group Trial 9401: Topoisomerase II α gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in *HER-2/neu*-amplified breast cancer. *J Clin Oncol* 24:2428-2436, 2006
20. Dowsett M, Hanna WM, Kockx M, et al: Standardization of HER2 testing: Results of an international proficiency-testing ring study. *Mod Pathol* 20:584-591, 2007
21. Kim C, Tang G, Baehner FL, et al: A comparison of estrogen receptor (ER) measurement by three methods in node-negative, estrogen receptor (ER)-positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PCR. *Breast Cancer Res Treat* 100:S295, 2006 (suppl 1; abstr 3116)
22. Paik S, Kim C, Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. *N Engl J Med* 358:1409-1411, 2008
23. Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. *Am J Surg Pathol* 29:1221-1227, 2005
24. Vanden Bempt I, van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. *J Clin Oncol* 26:4869-4874, 2008
25. Reinholz MM, Jenkins RB, Hillman D, et al: The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 36)

Glossary Terms

FISH (fluorescence in situ hybridization): In situ hybridization is a sensitive method that is generally used to detect specific gene sequences in tissue sections or cell preparations by hybridizing the complementary strand of a nucleotide probe to the sequence of interest. FISH uses a fluorescence probe to increase the sensitivity of in situ hybridization.

HER2 or HER-2 (human epithelial growth factor receptor-2): Also called ErbB2, HER-2/neu belongs to the EGFR family and is overexpressed in several solid tumors. Like EGFR, it is a tyrosine kinase receptor whose activation leads to proliferative signals within the cells. On activation, the HER family of receptors are known to form homodimers and heterodimers, each with a distinct signaling activity. Because HER-2 is the preferred dimerization partner when heterodimers are formed, it is important for signaling through ligands specific for any members of the family. It is typically overexpressed in several epithelial tumors.

Trastuzumab: A humanized anti-ErbB2 monoclonal antibody approved for treating patients whose breast cancers overexpress ErbB2 protein or demonstrate ErbB2 gene amplification, it is currently being tested in combination with other therapies.

Immunohistochemistry: The application of antigen-antibody interactions to histochemical techniques. Typically, a tissue section is mounted on a slide and is incubated with antibodies (polyclonal or monoclonal) specific to the antigen (primary reaction). The antigen-antibody signal is then amplified using a second antibody conjugated to a complex of peroxidase-antiperoxidase (PAP), avidin-biotin-peroxidase (ABC) or avidin-biotin alkaline phosphatase. In the presence of substrate and chromogen, the enzyme forms a colored deposit at the sites of antibody-antigen binding. Immunofluorescence is an alternate approach to visualize antigens. In this technique, the primary antigen-antibody signal is amplified using a second antibody conjugated to a fluorochrome. On UV light absorption, the fluorochrome emits its own light at a longer wavelength (fluorescence), thus allowing localization of antibody-antigen complexes.

HER2/CEP17: The number of copies of the HER2 gene divided by the number of copies of chromosome 17 (strictly the number of copies of the pericentric region of chromosome 17 to which the CEP17 FISH probe hybridizes).

Polysomy: At least one more copy of a chromosome than normal, ie the number of chromosomes is greater than 2 in a cell. Estimates of polysomy are usually not integer values because they are based on the average number of copies across multiple tumor cells between which the number of chromosomes present, or detected by the method used, often varies.